 Charlotte Wagner
Concepts (67)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 2 | 2023 | 171 | 0.860 |
Why?
| | Immunotherapy, Adoptive | 5 | 2026 | 342 | 0.860 |
Why?
| | Multiple Myeloma | 5 | 2026 | 309 | 0.840 |
Why?
| | Etoposide | 1 | 2024 | 168 | 0.810 |
Why?
| | Cyclophosphamide | 1 | 2024 | 266 | 0.800 |
Why?
| | Oligopeptides | 1 | 2024 | 266 | 0.730 |
Why?
| | Cisplatin | 1 | 2024 | 345 | 0.720 |
Why?
| | Immunoconjugates | 1 | 2023 | 138 | 0.710 |
Why?
| | Dexamethasone | 1 | 2024 | 366 | 0.700 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1965 | 0.470 |
Why?
| | B-Cell Maturation Antigen | 2 | 2025 | 17 | 0.430 |
Why?
| | Anemia, Aplastic | 2 | 2025 | 42 | 0.410 |
Why?
| | Stem Cell Transplantation | 2 | 2026 | 190 | 0.400 |
Why?
| | Antilymphocyte Serum | 1 | 2025 | 57 | 0.220 |
Why?
| | Antibodies, Bispecific | 1 | 2025 | 69 | 0.210 |
Why?
| | Antigens, CD19 | 1 | 2025 | 130 | 0.210 |
Why?
| | Paraproteinemias | 1 | 2024 | 5 | 0.210 |
Why?
| | Idarubicin | 1 | 2023 | 5 | 0.210 |
Why?
| | Anaphylaxis | 1 | 2025 | 102 | 0.200 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2025 | 231 | 0.200 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2025 | 193 | 0.190 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2023 | 134 | 0.180 |
Why?
| | Recurrence | 1 | 2024 | 1142 | 0.160 |
Why?
| | Treatment Outcome | 3 | 2024 | 11831 | 0.160 |
Why?
| | Retrospective Studies | 7 | 2026 | 17269 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 881 | 0.140 |
Why?
| | Simeprevir | 1 | 2018 | 5 | 0.140 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2018 | 44 | 0.130 |
Why?
| | Chronic Disease | 1 | 2023 | 1816 | 0.130 |
Why?
| | Protease Inhibitors | 1 | 2018 | 101 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1150 | 0.120 |
Why?
| | HIV Integrase Inhibitors | 1 | 2018 | 79 | 0.120 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2023 | 686 | 0.120 |
Why?
| | Aged | 6 | 2026 | 26125 | 0.120 |
Why?
| | Middle Aged | 6 | 2026 | 36176 | 0.100 |
Why?
| | Humans | 13 | 2026 | 145491 | 0.100 |
Why?
| | Male | 7 | 2026 | 72817 | 0.080 |
Why?
| | Female | 7 | 2026 | 78763 | 0.070 |
Why?
| | Adult | 7 | 2026 | 40707 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 1 | 2025 | 123 | 0.060 |
Why?
| | Staurosporine | 1 | 2023 | 22 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2025 | 427 | 0.050 |
Why?
| | Cytarabine | 1 | 2023 | 66 | 0.050 |
Why?
| | Benzoates | 1 | 2023 | 50 | 0.050 |
Why?
| | Hydrazines | 1 | 2023 | 37 | 0.050 |
Why?
| | Horses | 1 | 2025 | 227 | 0.050 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2023 | 51 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 411 | 0.050 |
Why?
| | Remission Induction | 1 | 2023 | 309 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2025 | 8326 | 0.050 |
Why?
| | Pyrazoles | 1 | 2023 | 517 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2023 | 842 | 0.040 |
Why?
| | Oxazines | 1 | 2018 | 37 | 0.030 |
Why?
| | Area Under Curve | 1 | 2018 | 329 | 0.030 |
Why?
| | Incidence | 1 | 2023 | 2915 | 0.030 |
Why?
| | Hepacivirus | 1 | 2018 | 244 | 0.030 |
Why?
| | Pyridones | 1 | 2018 | 208 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 378 | 0.030 |
Why?
| | Hepatitis C | 1 | 2018 | 257 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1046 | 0.030 |
Why?
| | Cohort Studies | 1 | 2025 | 5992 | 0.030 |
Why?
| | Mutation | 1 | 2023 | 4093 | 0.020 |
Why?
| | HIV-1 | 1 | 2018 | 905 | 0.020 |
Why?
| | Young Adult | 1 | 2025 | 14192 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 8039 | 0.010 |
Why?
| | Animals | 1 | 2025 | 38141 | 0.010 |
Why?
| | HIV Infections | 1 | 2018 | 3189 | 0.010 |
Why?
|
|
Wagner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|